Zacks Investment Research cut shares of BioNano Genomics (NASDAQ:BNGO) from a hold rating to a sell rating in a research note published on Thursday morning.

According to Zacks, “BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents. BioNano Genomics, Inc. is based in San Diego, United States. “

BNGO has been the subject of a number of other reports. ValuEngine cut BioNano Genomics from a buy rating to a hold rating in a report on Friday, December 21st. Maxim Group upgraded BioNano Genomics to a buy rating and set a $11.00 target price for the company in a report on Wednesday, March 6th. Finally, Roth Capital restated a buy rating on shares of BioNano Genomics in a report on Tuesday, February 5th.

Shares of NASDAQ:BNGO opened at $5.00 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.19 and a quick ratio of 4.72. BioNano Genomics has a 12-month low of $3.50 and a 12-month high of $10.00.

BioNano Genomics (NASDAQ:BNGO) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.14). The company had revenue of $4.01 million during the quarter, compared to analysts’ expectations of $3.71 million. On average, equities research analysts expect that BioNano Genomics will post -2.76 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in BNGO. Federated Investors Inc. PA purchased a new position in BioNano Genomics during the 3rd quarter valued at about $56,704,000. Sio Capital Management LLC purchased a new position in BioNano Genomics during the 3rd quarter valued at about $7,353,000. Monashee Investment Management LLC purchased a new position in BioNano Genomics during the 3rd quarter valued at about $1,300,000. Worth Venture Partners LLC boosted its holdings in BioNano Genomics by 1,666.6% during the 4th quarter. Worth Venture Partners LLC now owns 79,902 shares of the company’s stock valued at $417,000 after acquiring an additional 75,379 shares during the period. Finally, Millennium Management LLC purchased a new position in BioNano Genomics during the 4th quarter valued at about $254,000. Institutional investors own 11.50% of the company’s stock.

About BioNano Genomics

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics.

See Also: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Get a free copy of the Zacks research report on BioNano Genomics (BNGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.